141 related articles for article (PubMed ID: 34868336)
1.
Xiao S; Zhuo C; Zhuo C
Comput Math Methods Med; 2021; 2021():1175379. PubMed ID: 34868336
[TBL] [Abstract][Full Text] [Related]
2. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
3. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
[TBL] [Abstract][Full Text] [Related]
4. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
5. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
[TBL] [Abstract][Full Text] [Related]
6. [In vitro antibacterial activity of cefoperazone-sulbactam].
Zhang Y; Zhang J; Zhou L
Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):676-9. PubMed ID: 8731829
[TBL] [Abstract][Full Text] [Related]
7. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
Motohiro T; Nagai K; Yamada T; Oki S; Yamada T; Yoshinaga Y; Tsumura N; Oda K; Sakata Y; Kato H; Imai S; Morita J; Matsuo Y; Ikezawa S; Takahgashi K; Fukuda T; Yamashita Y; Aramaki M; Hayashi M; Yamakawa R; Ono-E ; Tananari Y; Tsutsumi T; Hoshuyama A; Aida K
Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
[TBL] [Abstract][Full Text] [Related]
8. [Effects of sulbactam on the activity of cefoperazone against various clinical isolates].
Uete T; Matsuo K
Jpn J Antibiot; 1989 Apr; 42(4):896-909. PubMed ID: 2769941
[TBL] [Abstract][Full Text] [Related]
9. [Clinical laboratory approach for estimating effective administrative dose of sulbactam/cefoperazone].
Uete T; Matsuo K
Jpn J Antibiot; 1988 Nov; 41(11):1578-90. PubMed ID: 3210296
[TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial activity of sulbactam/cefoperazone. Comparison with other new cephems].
Deguchi K; Yokota N; Koguchi M; Fukayama S; Nishimura Y; Nakane Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1987 Oct; 40(10):1752-61. PubMed ID: 3444015
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
[TBL] [Abstract][Full Text] [Related]
12. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
Suzuki K; Horiba M
Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
17. [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
Iwata S; Sato Y; Iwasaki Y; Hayano S; Wakabayashi R; Kojima Y; Akita H; Sunakawa K; Oikawa T; Osano M
Jpn J Antibiot; 1984 Oct; 37(10):1831-45. PubMed ID: 6094863
[TBL] [Abstract][Full Text] [Related]
18. [Basic and clinical evaluation of sulbactam/cefoperazone in the field of pediatrics].
Toyonaga Y; Kurosu Y; Nakamura H; Sugita M; Takahashi T; Hori M
Jpn J Antibiot; 1984 Dec; 37(12):2457-77. PubMed ID: 6098740
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America.
Sader HS; Carvalhaes CG; Streit JM; Castanheira M; Flamm RK
Int J Infect Dis; 2020 Feb; 91():32-37. PubMed ID: 31715325
[TBL] [Abstract][Full Text] [Related]
20. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
